{
  "actions": [
    {
      "acted_at": "2019-03-05",
      "action_code": "10000",
      "references": [],
      "text": "Introduced in Senate",
      "type": "action"
    },
    {
      "acted_at": "2019-03-05",
      "action_code": "",
      "committees": [
        "SSHR"
      ],
      "references": [],
      "status": "REFERRED",
      "text": "Read twice and referred to the Committee on Health, Education, Labor, and Pensions.",
      "type": "referral"
    }
  ],
  "amendments": [
    {
      "amendment_id": "samdt1588-116",
      "amendment_type": "samdt",
      "chamber": "s",
      "number": "1588"
    }
  ],
  "bill_id": "s658-116",
  "bill_type": "s",
  "by_request": false,
  "committee_reports": [],
  "committees": [
    {
      "activity": [
        "referral"
      ],
      "committee": "Senate Health, Education, Labor, and Pensions",
      "committee_id": "SSHR"
    }
  ],
  "congress": "116",
  "cosponsors": [],
  "enacted_as": null,
  "history": {
    "active": false,
    "awaiting_signature": false,
    "enacted": false,
    "vetoed": false
  },
  "introduced_at": "2019-03-05",
  "number": "658",
  "official_title": "A bill to provide for an accelerated approval pathway for certain drugs that are authorized to be lawfully marketed in other countries.",
  "popular_title": null,
  "related_bills": [],
  "short_title": "Accelerated Drug Approval for Prescription Therapies Act",
  "sponsor": {
    "bioguide_id": "B001310",
    "district": null,
    "name": "Braun, Mike",
    "state": "IN",
    "title": "Sen.",
    "type": "person"
  },
  "status": "REFERRED",
  "status_at": "2019-03-05",
  "subjects": [
    "Drug safety, medical device, and laboratory regulation",
    "Health",
    "Manufacturing",
    "Marketing and advertising",
    "Medical research",
    "Prescription drugs"
  ],
  "subjects_top_term": "Health",
  "summary": {
    "as": "Introduced in Senate",
    "asOf": "2019-03-05",
    "date": "2021-08-04T15:50:40Z",
    "text": "Accelerated Drug Approval for Prescription Therapies Act or the ADAPT Act\n\nThis bill authorizes the Food and Drug Administration (FDA)to create an expedited drug approval process specifically for drugs that are currently approved for sale in certain countries (i.e., a European Economic Area member country, Australia, Canada, Israel, Japan, New Zealand, South Africa, or Switzerland) and meet certain criteria. Such criteria shall include establishing that (1) the drug is safe and effective, (2) all relevant U.S. patents or legal exclusivities have expired, and (3) the United States has a public health or unmet medical need for the drug.\n\nThe FDA must process and review an application under this bill within 180 days of submission."
  },
  "titles": [
    {
      "as": null,
      "is_for_portion": false,
      "textVersionCode": null,
      "title": "ADAPT Act",
      "type": "display"
    },
    {
      "as": "introduced",
      "is_for_portion": false,
      "textVersionCode": null,
      "title": "Accelerated Drug Approval for Prescription Therapies Act",
      "type": "short"
    },
    {
      "as": "introduced",
      "is_for_portion": false,
      "textVersionCode": null,
      "title": "ADAPT Act",
      "type": "short"
    },
    {
      "as": "introduced",
      "is_for_portion": false,
      "textVersionCode": null,
      "title": "A bill to provide for an accelerated approval pathway for certain drugs that are authorized to be lawfully marketed in other countries.",
      "type": "official"
    }
  ],
  "updated_at": "2022-11-01T17:17:27Z",
  "url": "https://www.govinfo.gov/bulkdata/BILLSTATUS/116/s/BILLSTATUS-116s658.xml"
}